Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NFnhU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HINWlEPTB;MD62NVI{PyEQvF2= NELaWHNUSU6JRWK=
H4 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX0c4xzUUN3ME2wMlY3OjhizszN M2fQdnNCVkeHUh?=
PA-1 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP5blhzUUN3ME2wMlg4ODl4IN88US=> M4m3SXNCVkeHUh?=
NKM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwMES5N|Eh|ryP M2fpcXNCVkeHUh?=
NEC8 NXfFb2ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrO2hKSzVyPUGuNlE2PzJizszN MWLTRW5ITVJ?
EoL-1-cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4fZhxUUN3ME2xMlI3PzBzIN88US=> NET4bYhUSU6JRWK=
K5 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LSVmlEPTB;MT60NlA4OiEQvF2= M4D1[3NCVkeHUh?=
QIMR-WIL NFnucpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD1zLk[wPFU1KM7:TR?= MoX2V2FPT0WU
MOLT-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTCTWM2OD1zLke4OlA1KM7:TR?= NUnTXGh6W0GQR1XS
CHP-212 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHVZ4xKSzVyPUGuPFE{PjlizszN M2XyNnNCVkeHUh?=
CTB-1 NVvDUXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwMEKyOFYh|ryP NFvxVnBUSU6JRWK=
MOLT-4 M2LM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJwM{K4OVMh|ryP MV3TRW5ITVJ?
A101D NEHUPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7HRZRPUUN3ME2yMlM2ODFizszN M36zZnNCVkeHUh?=
DOHH-2 NYPiSXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrsZlBKSzVyPUKuOFIzPzlizszN M2HCWHNCVkeHUh?=
ES4 M3vwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf0TWM2OD1{LkSzNVU2KM7:TR?= NV7RUWlTW0GQR1XS
SW780 M3vMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwNUC4PFMh|ryP MU\TRW5ITVJ?
VA-ES-BJ M4fr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwNUSxNUDPxE1? MXTTRW5ITVJ?
RPMI-8866 NHrFTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqxTWM2OD1{LkW2NlE1KM7:TR?= MULTRW5ITVJ?
ML-2 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwNU[1O|Yh|ryP NUK0bIg4W0GQR1XS
MSTO-211H MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CzbWlEPTB;Mj61O|Q2OSEQvF2= MmG1V2FPT0WU
JVM-3 M4TH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBR2lEPTB;Mj61PVMzPCEQvF2= M4D1OnNCVkeHUh?=
A3-KAW NXWyVpF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfXPWFEUUN3ME2yMlYyQDF6IN88US=> NE\IUFlUSU6JRWK=
DK-MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELnSoxKSzVyPUKuOlI1PzFizszN NFH0dmlUSU6JRWK=
LNCaP-Clone-FGC MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwNkSzNVgh|ryP NEjRSJdUSU6JRWK=
HT-144 NEC3NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOxboRKSzVyPUKuOlQ2PzdizszN MVLTRW5ITVJ?
NB69 NG\4dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iOmlEPTB;Mj62OVM{PCEQvF2= MoDFV2FPT0WU
A172 NH7PNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwNke1PFgh|ryP MXnTRW5ITVJ?
RS4-11 MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;6[ndKSzVyPUKuO|I1ODdizszN NIDvc2RUSU6JRWK=
DU-4475 M1LtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwN{m1NFIh|ryP NV\xOY9zW0GQR1XS
SJSA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf6d|h1UUN3ME2yMlgzPTV4IN88US=> NYXt[nFkW0GQR1XS
BV-173 NInWWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwOES0N|kh|ryP MojPV2FPT0WU
U-2-OS NXy1OVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjMPFA5UUN3ME2yMlkyODdizszN NVLT[4RsW0GQR1XS
CHP-134 NXv3cHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwOUO4PFIh|ryP MkTaV2FPT0WU
D-502MG NHfCXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HDRWlEPTB;Mj65O|E2PCEQvF2= MljhV2FPT0WU
KS-1 M{nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfVT3pEUUN3ME2zMlAyPjJ|IN88US=> MlfTV2FPT0WU
A204 NIPVT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj2R2RKSzVyPUOuNFU2QDhizszN M4nUeHNCVkeHUh?=
KGN M2rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNwMEi0PVYh|ryP MVjTRW5ITVJ?
NCI-H292 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\oWHFKSzVyPUOuNVIxOjhizszN NHm1bYpUSU6JRWK=
CAKI-1 NETIO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUUZJKSzVyPUOuNVI3QTRizszN M1LLZnNCVkeHUh?=
C2BBe1 NH64ZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ubVVCUUN3ME2zMlE4ODJ4IN88US=> M1OyTHNCVkeHUh?=
NB10 NUC2W|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfTcHhoUUN3ME2zMlIxQTZ4IN88US=> M3LTUnNCVkeHUh?=
MHH-NB-11 M4jJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;jTWM2OD1|LkK2PFI4KM7:TR?= Ml\OV2FPT0WU
NCI-SNU-1 NUjUT2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPKTWM2OD1|LkK3PFQ{KM7:TR?= NUThOo52W0GQR1XS
HCT-116 NGnTW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\IfWlEPTB;Mz6zNFM{PSEQvF2= NGPPO21USU6JRWK=
G-401 NYXIZ49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYOWlEPTB;Mz6zOlMzOiEQvF2= MnPGV2FPT0WU
MN-60 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrrdJJKSzVyPUOuOFQxQTJizszN MoGzV2FPT0WU
SW982 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3aXW9OUUN3ME2zMlUxQDR6IN88US=> MUDTRW5ITVJ?
RKO NUHDfHZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;EW2lEPTB;Mz61N|k{PiEQvF2= NWfWZYdMW0GQR1XS
D-283MED NWnlV25UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXpcJFlUUN3ME2zMlU4QTh4IN88US=> M1\6bXNCVkeHUh?=
LB996-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P6S2lEPTB;Mz62NlU2QCEQvF2= M1\uPHNCVkeHUh?=
A549 M37jXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnMTWM2OD1|Lk[zOVUzKM7:TR?= MYXTRW5ITVJ?
LB2241-RCC NWn5S4s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPX[2dQUUN3ME2zMlY2PzB6IN88US=> MlfnV2FPT0WU
SK-HEP-1 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPWTWM2OD1|Lke0Nlk4KM7:TR?= MWPTRW5ITVJ?
G-402 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPsfJJSUUN3ME2zMlgxQDN{IN88US=> NWPHXmdTW0GQR1XS
GOTO Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljRTWM2OD1|Lki0N|M{KM7:TR?= NEPIdVRUSU6JRWK=
LOXIMVI NFr5O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorlTWM2OD1|Lki1Olc2KM7:TR?= NFXwUZNUSU6JRWK=
NH-12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX4TWM2OD12LkCxPVU6KM7:TR?= NEfVWIxUSU6JRWK=
CTV-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLTTWM2OD12LkC3PVc{KM7:TR?= NEnlXJNUSU6JRWK=
CP50-MEL-B NGm3cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRwMkSzPVIh|ryP MYDTRW5ITVJ?
RH-18 NV7SRZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq5XGZwUUN3ME20MlI4PzB4IN88US=> M363SHNCVkeHUh?=
NB17 M2XTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnPbnhKSzVyPUSuN|E4PjhizszN MWXTRW5ITVJ?
A375 NGXLTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnvTYQzUUN3ME20MlM{PTJ2IN88US=> NFP5NHpUSU6JRWK=
IST-MES1 M2nXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTHTmIzUUN3ME20MlQyPDFzIN88US=> MofuV2FPT0WU
MZ2-MEL M13sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV75fJllUUN3ME20MlUxOTV3IN88US=> MkewV2FPT0WU
CAL-54 NYG2[3RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzTWM2OD12LkWzNFE6KM7:TR?= NUTDbFhiW0GQR1XS
NCI-H28 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG5TWM2OD12Lk[yO|E4KM7:TR?= MYDTRW5ITVJ?
D-247MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\FfWlEPTB;ND63OVA4OiEQvF2= NV6wd4UzW0GQR1XS
NCI-H460 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULGSFI6UUN3ME20MlkyOTJ5IN88US=> NF\XVVhUSU6JRWK=
MCF7 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT0XFRKSzVyPUWuOFQzPDRizszN NVzlXGN5W0GQR1XS
697 NEXNeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTVwNES1OUDPxE1? MlP3V2FPT0WU
ONS-76 M2npfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jze2lEPTB;NT61O|AxQSEQvF2= M3TnZnNCVkeHUh?=
C32 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTVwNkCwNlkh|ryP NETqSYpUSU6JRWK=
OS-RC-2 NGLxeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwN{O4PFch|ryP Mk\yV2FPT0WU
MEL-HO MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTVwOEW2Olch|ryP NEP0WlZUSU6JRWK=
LoVo M{n5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LNXWlEPTB;Nj6wNVYzPCEQvF2= M3SySHNCVkeHUh?=
AGS NFrWcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXITWM2OD14LkG0PFI5KM7:TR?= M1;oNXNCVkeHUh?=
GI-ME-N M4PEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j6SmlEPTB;Nj6yNlQzOSEQvF2= MXTTRW5ITVJ?
H-EMC-SS NHnsVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PBNGlEPTB;Nj6zPFYh|ryP M1q5cHNCVkeHUh?=
RVH-421 M33sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhcIRKUUN3ME22MlQzPDJ6IN88US=> M{TIeHNCVkeHUh?=
SW954 NEPke4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrrVXRKSzVyPU[uOVU2PzJizszN NX3wZlRZW0GQR1XS
NB5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTZwNU[xPFMh|ryP MXjTRW5ITVJ?
NCI-H2122 NXm2OoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XMOGlEPTB;Nj61PFc6OyEQvF2= MYPTRW5ITVJ?
AM-38 NW\idG92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe2TWM2OD14Lke1OlM6KM7:TR?= NEXEO5pUSU6JRWK=
KNS-81-FD NXjGNW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe2XlZOUUN3ME22Mlc3PDl2IN88US=> MlzoV2FPT0WU
LS-513 M1\Cc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nNemlEPTB;Nj63PVAzPiEQvF2= M1jhfXNCVkeHUh?=
A427 M1TqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX3bJRKSzVyPU[uPFc5OjlizszN MU\TRW5ITVJ?
WM-115 M3rDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nHeWlEPTB;Nj65N|I{KM7:TR?= NIHNOVJUSU6JRWK=
COLO-829 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;CR2NjUUN3ME23MlI1OTh6IN88US=> NYnVVplYW0GQR1XS
NCI-H1650 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n1dmlEPTB;Nz6zPVIzQCEQvF2= NUXSNYl7W0GQR1XS
NCI-H358 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7nTWM2OD15LkS0PFc6KM7:TR?= M1[yU3NCVkeHUh?=
HT-1080 NVOxWmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj4WoFxUUN3ME23MlQ5OjV2IN88US=> NFfOOXdUSU6JRWK=
HCC2218 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTdwNkK5O{DPxE1? MnG1V2FPT0WU
NCI-H661 NH\aSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInQN|VKSzVyPUeuPFcxPjlizszN NHfWVIZUSU6JRWK=
KM-H2 M4q5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj3TWM2OD15Lki4Olk1KM7:TR?= M4DZfnNCVkeHUh?=
RPMI-2650 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyycotMUUN3ME23Mlk1PDF2IN88US=> NILp[GJUSU6JRWK=
NCI-H226 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3R[29KSzVyPUiuNlEyOjJizszN MlzqV2FPT0WU
MKN45 NHSyVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e4dmlEPTB;OD6yOlYxOiEQvF2= NGq0RWlUSU6JRWK=
D-392MG M1XmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRThwNUK3NlIh|ryP MVnTRW5ITVJ?
RCC10RGB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXyclJTUUN3ME24Mlg3Pjl3IN88US=> MWjTRW5ITVJ?
CAL-51 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPLNlhJUUN3ME25MlExOjVzIN88US=> MWjTRW5ITVJ?
COLO-678 NVjLbnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvSXIxxUUN3ME25MlMzQDFzIN88US=> NInqeZJUSU6JRWK=
SK-MEL-24 NU[0WlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfxNJJKSzVyPUmuOVU5PTZizszN NIOwbVNUSU6JRWK=
SK-MEL-30 M{O1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqe2lEPTB;OT65OFQ4PiEQvF2= MX3TRW5ITVJ?
MMAC-SF NHHxdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhS4tKSzVyPUGwMlM6PjFizszN MWrTRW5ITVJ?
NTERA-S-cl-D1 NEPTTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[0[nNKSzVyPUGwMlY2ODhizszN MXvTRW5ITVJ?
NB12 NGjwbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFzLkWwN{DPxE1? MXHTRW5ITVJ?
UACC-257 M3\3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvMTWM2OD1zMT64Olk2KM7:TR?= MorHV2FPT0WU
LAN-6 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFzLkm5Nlgh|ryP M{S0V3NCVkeHUh?=
SW1573 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorXTWM2OD1zMj6zNFg3KM7:TR?= MVLTRW5ITVJ?
NMC-G1 M1nQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[0XXpKSzVyPUGyMlQyPzVizszN NH\yclVUSU6JRWK=
SHP-77 M4Lpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi3TWM2OD1zMj61OVc1KM7:TR?= MlTuV2FPT0WU
IGROV-1 NGGxfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G2WGlEPTB;MUKuOlU4OyEQvF2= NWfnXJZkW0GQR1XS
22RV1 M323NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3SR4xoUUN3ME2xNk45ODV7IN88US=> MXnTRW5ITVJ?
SK-MEL-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jycGlEPTB;MUOuN|k4OyEQvF2= NVG5SYtuW0GQR1XS
NCI-H1563 NH7TOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|LkSyNFIh|ryP M3u4S3NCVkeHUh?=
IGR-1 NEfHUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XCWGlEPTB;MUSuNFM1PyEQvF2= M1Th[nNCVkeHUh?=
EW-3 M1f0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF2LkG2N|kh|ryP MVnTRW5ITVJ?
JEG-3 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rTPWlEPTB;MUSuOFk2OyEQvF2= MV3TRW5ITVJ?
ES3 Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofhTWM2OD1zND62OVYzKM7:TR?= MX\TRW5ITVJ?
MDA-MB-175-VII M4PZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\UUG57UUN3ME2xOE44OTFzIN88US=> NV61WJp2W0GQR1XS
P30-OHK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHXbGhJUUN3ME2xOU4xPDl4IN88US=> MYXTRW5ITVJ?
GP5d NVjtbmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv2TVhKSzVyPUG1MlE1PjZizszN NHHEb4RUSU6JRWK=
HMV-II MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF3LkOzN|Mh|ryP NGfhZ4pUSU6JRWK=
COLO-679 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDX[3dKSzVyPUG1MlUxOSEQvF2= M3X2W3NCVkeHUh?=
JAR M4LDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHLTWM2OD1zNT63NlA2KM7:TR?= MknDV2FPT0WU
NCI-H1666 M2HnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ucFRwUUN3ME2xOU46Ozl7IN88US=> NF75XnRUSU6JRWK=
SW48 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF3Lkm1NVYh|ryP MWjTRW5ITVJ?
NCI-H720 M{nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PGNGlEPTB;MUWuPVk5QSEQvF2= M3XNNXNCVkeHUh?=
HT-1197 NWP6XmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS4TWM2OD1zNj6wN|UzKM7:TR?= NF;ibItUSU6JRWK=
HL-60 NFm5cnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1foO2lEPTB;MU[uNFM5PCEQvF2= MkH0V2FPT0WU
BEN MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjLOlJoUUN3ME2xOk42PjN6IN88US=> NF:xXmZUSU6JRWK=
HAL-01 NGKxbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqwUlBKSzVyPUG2Mlg6ODlizszN M{PwNHNCVkeHUh?=
SW900 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle5TWM2OD1zNj65NVMzKM7:TR?= M1TO[HNCVkeHUh?=
SBC-1 M13ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHVTWM2OD1zNz61OFI6KM7:TR?= MUPTRW5ITVJ?
SH-4 NXTGV5V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kNGlEPTB;MUeuOVg1OSEQvF2= NFvZe4hUSU6JRWK=
UACC-62 NEPW[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M321UmlEPTB;MUeuO|Y{PyEQvF2= NHrLdZFUSU6JRWK=
BHT-101 NW\aNmN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnyT2FlUUN3ME2xPU45PzB3IN88US=> M3Hxc3NCVkeHUh?=
DB M4[2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvqTG41UUN3ME2yNU42PjR7IN88US=> NFfKZXRUSU6JRWK=
SK-MEL-1 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmVoNKSzVyPUKxMlU5PzJizszN M1jyeHNCVkeHUh?=
NCI-H747 NVTTb4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XpRWlEPTB;MkKuO|M4QSEQvF2= NWG5ZVY5W0GQR1XS
SK-LU-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ|LkO1NlQh|ryP MXTTRW5ITVJ?
KG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ldHI3UUN3ME2yN{41QTR4IN88US=> NGjCb21USU6JRWK=
LXF-289 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknBTWM2OD1{Mz63NVQh|ryP NYPKcm9lW0GQR1XS
HCC1954 M4fGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;GTWM2OD1{ND64PFQ1KM7:TR?= M{DQVnNCVkeHUh?=
Ramos-2G6-4C10 NGXjb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M124RWlEPTB;Mk[uOFk5OSEQvF2= MX7TRW5ITVJ?
DBTRG-05MG M2fZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrnTWM2OD1{Nj62OFg5KM7:TR?= M2rRT3NCVkeHUh?=
NCI-H2052 M{LSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\zPWhXUUN3ME2yO{42Pjh2IN88US=> NHrIbm5USU6JRWK=
RMG-I NVnDdIVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrY[JZKSzVyPUK5MlQyOzlizszN NGjkNmJUSU6JRWK=
H9 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPyTWM2OD1|MT6zNFA5KM7:TR?= MkTyV2FPT0WU
GR-ST MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rvTmlEPTB;M{KuOFQ2OyEQvF2= MVfTRW5ITVJ?
Mo-T NGSyU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\FS25XUUN3ME2zNk42ODR4IN88US=> MmXXV2FPT0WU
SW1088 NVnncpp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHySG1PUUN3ME2zNk46QDBzIN88US=> MkfDV2FPT0WU
LB2518-MEL NYXs[G5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fncWlEPTB;M{OuNFc6PyEQvF2= MVrTRW5ITVJ?
NCI-H82 M{PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2wWW1KSzVyPUOzMlE3PjFizszN NHm3V3ZUSU6JRWK=
LAMA-84 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN2Lk[wO|Mh|ryP M4[1TnNCVkeHUh?=
KYSE-450 NHTUV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfheGxyUUN3ME2zOE43Pzd4IN88US=> NEjoWHNUSU6JRWK=
LU-99A NXXZZnJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULafWY1UUN3ME2zOU4xODB5IN88US=> M1rxO3NCVkeHUh?=
BE-13 M{DLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHhTmNXUUN3ME2zOU43PTR3IN88US=> NFPUPXZUSU6JRWK=
GAK NVr4NIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN3Lk[5OUDPxE1? NGfHe4VUSU6JRWK=
NCI-H1573 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN3Lki4NVgh|ryP NVzjS2FwW0GQR1XS
AsPC-1 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi0SlFKSzVyPUO2MlE2OjdizszN MX\TRW5ITVJ?
HDLM-2 M2jrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN4LkOxOkDPxE1? NV\RfGJtW0GQR1XS
NCI-H441 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTSN4VKSzVyPUO3MlA3QTFizszN NHjCPHRUSU6JRWK=
CAL-27 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jrV2lEPTB;M{euO|I{OSEQvF2= MUnTRW5ITVJ?
OVCAR-3 NGDCcmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTN7LkOxPFEh|ryP M363RnNCVkeHUh?=
RPMI-8226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPZdXV4UUN3ME2zPU42QThizszN M1\FWHNCVkeHUh?=
EFO-21 M{fRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrveXdKSzVyPUSwMlU5OTRizszN NGfZdYhUSU6JRWK=
SNU-C2B M4jIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;zTWM2OD12MT61NFg1KM7:TR?= NHTQboVUSU6JRWK=
VM-CUB-1 NVrJfJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGzN3d[UUN3ME20N{45ODN5IN88US=> MXHTRW5ITVJ?
NCI-H2087 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnP[IZlUUN3ME20OU4xOjN|IN88US=> NH7H[4pUSU6JRWK=
EW-16 NIfjdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PIVWlEPTB;NE[uN|E{PyEQvF2= MoDFV2FPT0WU
SK-N-AS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi0TWM2OD12Nj63NVY4KM7:TR?= M1zZSnNCVkeHUh?=
COR-L105 NYnBUldMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR4Lki4OVch|ryP NYXWWZhPW0GQR1XS
DEL M2X4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTod5VYUUN3ME20PE4xPDJ7IN88US=> MYHTRW5ITVJ?
JVM-2 NWW2bpdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G4T2lEPTB;NEiuNFU2QCEQvF2= MmXDV2FPT0WU
KARPAS-45 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK3N4xKSzVyPUS5MlQ2OzhizszN NFj0PXBUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID